Fibrosis/Cirrhosis
Fibrosis & Cirrhosis
Hepatitis C Cirrhosis Patients with Sustained Treatment Response Have Lower Risk of Death
- Details
- Category: HCV Treatment
- Published on Thursday, 27 December 2012 00:00
- Written by Liz Highleyman
Hepatitis C patients with cirrhosis who achieve sustained virological response to interferon-based therapy have a reduced risk of all-cause mortality, liver-related death or transplantation, liver cancer, and liver failure compared with non-responders, according to a study described in the December 26, 2012, issue of JAMA.
AASLD 2012: When Are HCV Direct-Acting Antivirals Needed, Who Should Be Prioritized?
- Details
- Category: Liver Cancer/HCC
- Published on Monday, 26 November 2012 00:00
- Written by Rob Camp
When resources for hepatitis C treatment with new direct-acting antivirals are limited, findings from the U.S. suggest that previously untreated people with low HCV viral loads may stand a good chance of achieving sustained virological response without adding telaprevir or boceprevir to pegylated interferon and ribavirin, researchers reported at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) this month in Boston. A related study suggests that younger hepatitis C patients with advanced liver disease should be prioritized for treatment with the new drugs. 
AASLD 2012: Telaprevir Twice-daily Works as Well as Every 8 Hours, Safe for Hep C Patients with Cirrhosis
- Details
- Category: HCV Treatment
- Published on Tuesday, 20 November 2012 00:00
- Written by Liz Highleyman
The HCV protease inhibitor telaprevir (Incivek) taken twice-daily with pegylated interferon plus ribavirin is as likely to produce sustained virological suppression as the approved 3-times-daily schedule, with similar safety and tolerability even for people with advanced liver fibrosis, according to study findings presented last week at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) in Boston. 
AASLD 2012: Nucleoside Analogs Reduce Hepatitis B Liver Cancer Risk, Cirrhosis Remains a Concern
- Details
- Category: HBV Treatment
- Published on Sunday, 25 November 2012 00:00
- Written by Liz Highleyman
Treatment of chronic hepatitis B with nucleoside/nucleotide analogs including lamivudine (Epivir-HBV) and entecavir (Baraclude) can reduce the risk of developing hepatocellular carcinoma, including cancer recurrence after successful resection, according to studies presented at the recent American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) and published in the Journal of the American Medical Association. 
AASLD 2012: Simeprevir Safe and Effective for Hepatitis C Patients With Cirrhosis
- Details
- Category: HCV Treatment
- Published on Monday, 19 November 2012 00:00
- Written by Liz Highleyman
The HCV protease inhibitor simeprevir (formerly TMC435) is generally safe and well-tolerated in people with advanced liver fibrosis or cirrhosis, and improves sustained response rates when added to pegylated interferon and ribavirin, researchers reported at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) last week in Boston. Related presentations showed that simeprevir is not implicated in drug-drug interactions with immunosuppressive agents or oral contraceptives.
More Articles...
- AASLD 2012: Sofosbuvir + GS-5885 + Ribavirin Shows High Early Response Rates for Genotype 1 HCV
- AASLD 2012: Sofosbuvir + Daclatasvir Dual Regimen Cures Most Patients with HCV Genotypes 1, 2, or 3
- AASLD 2012: Daclatasvir + Asunaprevir + BMS-791325 Cures Hard-to-treat Hepatitis C Patients
- AASLD 2012: Tenofovir Safe and Effective for Long-term Hepatitis B Treatment with Little Bone Loss
Web Design and Development by